Journal walks back 'seriously flawed' study critical of Merck's Gardasil
Citing "seriously flawed" methodology and "unjustified" claims, the journal Vaccine has permanently withdrawn a previously published study critical of Merck's Gardasil.
Widening the field further, Vaxart, Immunovaccine and Mayo Clinic are joining a slew of biotechs and pharmas either exploring or embarking on Zika vaccine development. Read more >>
U.K. rejects petition demanding meningitis B vaccine for all children
The U.K. rolled out its meningitis B vaccination program for babies in September, becoming the first country to add GlaxoSmithKline's ($GSK) Bexsero to its routine schedule. A petition demanding that it be expanded for all children quickly gathered steam. The Department of Health rejected the petition on Wednesday, saying that offering the jab to all children would not be cost-effective. Read more >>
TOP HEADLINES
Featured Story
Health agencies inform on Zika vaccine timeline
Multiple public health authorities have given insight to the timing of Zika vaccine development, with the WHO now stating that any vaccine may be too late for the current outbreak, a similar situation to the one the world experienced in the Ebola epidemic.
Valneva scores $42M supply contract with DOD
Valneva currently markets Ixiaro, a Japanese encephalitis vaccine and Dukoral, the cholera vaccine it acquired from Johnson & Johnson in 2015. Now, the Lyon, France-based vaccine maker is building on its relationship with the U.S. Department of Defense with a new $42 million supply contract for Ixiaro.
Analyst: Mitsubishi Tanabe's tobacco-based flu jab could have 'significant impact' on market
Following Mitsubishi Tanabe's announcement that its tobacco-based flu vaccine could hit the market by 2018 or 2019, a GlobalData analyst has lauded the Japanese company's candidate as poised to "take over" the flu vaccine market from traditional egg-based vaccines.
Duke, NIAID track HIV evolution with eyes on creating a vaccine
A team led by the Duke Human Vaccine Institute and the National Institute of Allergy and Infectious Diseases has tracked the evolution of HIV and the body's corresponding immune response, hoping now to turn the knowledge gained into an experimental vaccine.
Novavax explores Zika vaccine R&D effort as virus continues to spread
Vaccine companies and research organizations worldwide continue to race against Zika, with a new entrant emerging in Novavax. The biotech announced it's conducting preliminary Zika research in a week that saw several other developments in the field.
Sanofi digs into details on hastened Zika effort
Just last month, Sanofi became the first Big Pharma player to enter the Zika vaccine R&D space as its peers calculated their responses and weighed their options. Now, the French pharma is taking it a step further, outlining its plans to devote dozens of scientists to the field in a move aimed at expediting its vaccine development.
From Our Sister Sites
- FierceBiotech
- FierceBiotechIT
- FierceBiotechResearch
- FierceDrugDelivery
- FierceMedicalDevices
- FierceVaccines
- FiercePharma
- FiercePharmaAsia
- FiercePharmaManufacturing
- FierceCRO
- FierceDiagnostics
- FiercePharmaMarketing
- FierceAnimalHealth
- More Fierce Network sites
Amgen just won the first battle in a cholesterol-drug patent war that could be worth hundreds of millions in royalties per year. A Delaware jury decided Sanofi and Regeneron's PCSK9 drug Praluent did indeed step on Amgen's patents in the field.
You'd think Valeant Pharmaceuticals would abandon its sugar-coating strategy and just tell it like it is. CEO J. Michael Pearson promised earlier this month that no other shoes would drop, and boy, did they drop yesterday, with terrible 2016 guidance, a technical default on billions in debt--et cetera. Yet as VRX plummeted, Pearson was using the same "we'll fix it" language he's used since his company caught the spotlight last year.
POPULAR COMMENT THREADS